J.C.-H. Yang
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 10
- Oncology 10
- Lung Cancer Research Studies 8
- Cancer Immunotherapy and Biomarkers 3
- HER2/EGFR in Cancer Research 2
- Co-authors
- Hideo Saka (1 shared paper)Kenneth S. Thress (1 shared paper)Melanie M. Frigault (1 shared paper)Karthick Vishwanathan (1 shared paper)Yuichiro Ohe (1 shared paper)Kōichi Goto (1 shared paper)Helena A. Yu (1 shared paper)Myung‐Ju Ahn (1 shared paper)
- Journals
- Annals of Oncology (10 papers)Journal of Thoracic Oncology (1 paper)The Chinese-German Journal of Clinical Oncology (1 paper)
- Partner nations
- TaiwanUnited StatesSouth Korea
In The Last Decade
J.C.-H. Yang
12 papers receiving 362 citations
J.C.-H. Yang's Hit Papers
Peers
Comparison fields: 5 of 30
- Oncology 211
- Pulmonary and Respiratory Medicine 244
- Cancer Research 35
- Hepatology 12
- Immunology 29
Countries citing papers authored by J.C.-H. Yang
This map shows the geographic impact of J.C.-H. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C.-H. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C.-H. Yang more than expected).
Fields of papers citing papers by J.C.-H. Yang
This network shows the impact of papers produced by J.C.-H. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C.-H. Yang. The network helps show where J.C.-H. Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside J.C.-H. Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer Hit paper breakdown → | 2020 | 314 |
| 2 | 2017 | 10 | |
| 3 | 2016 | 10 | |
| 4 | 2016 | 8 | |
| 5 | 2019 | 4 | |
| 6 | 2022 | 4 | |
| 7 | 2020 | 4 | |
| 8 | 2019 | 3 | |
| 9 | 2021 | 3 | |
| 10 | 2019 | 2 | |
| 11 | 2005 | 2 | |
| 12 | 2016 | 1 |
About J.C.-H. Yang
J.C.-H. Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Genetics, having authored 12 papers that have together received 365 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer therapeutics and mechanisms (3 papers), HER2/EGFR in Cancer Research (2 papers), Intraperitoneal and Appendiceal Malignancies (1 paper), Chronic Lymphocytic Leukemia Research (1 paper) and Hepatocellular Carcinoma Treatment and Prognosis (1 paper). The work is most often cited by research in Oncology (211 citations), Pulmonary and Respiratory Medicine (244 citations), Cancer Research (35 citations), Hepatology (12 citations) and Immunology (29 citations). J.C.-H. Yang has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Hideo Saka, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Yuichiro Ohe, Kōichi Goto, Helena A. Yu, Myung‐Ju Ahn, Seung‐Whan Kim and Suresh S. Ramalingam. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology and The Chinese-German Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.